We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Beck, J. R., Kassirer, J. P., & Pauker, S. G.A convenient approximation of life expectancy; The “DEALE.”American Journal of Medicine, 1982, 73, 863–97.CrossRefGoogle ScholarPubMed
2
2.Drummond, M. F., Stoddart, G. L., & Torrance, G. W.Methods for the economic evaluation of health care programmes. Oxford, U.K.: Oxford University Press, 1987.Google Scholar
3
3.Johannesson, M., & Jönsson, B. Cost-effectiveness analysis of hypertension treatment — Methodological issues. CMT Report, Linköping, Sweden: Linköping University Center for Medical Technology Assessment, 1990, 5.Google Scholar
4
4.Keeler, E., & Cretin, S.Discounting of life savings and other non-monetary effects. Management Science, 1983, 29, 300–06.CrossRefGoogle Scholar
5
5.Martens, L., & Van Doorslaer, E.Dealing with discounting: An application to the cost-effectiveness of intracoronary thrombolysis with streptokinase. International Journal of Technology Assessment in Health Care, 1990, 6, 139–45.CrossRefGoogle Scholar
6
6.Rosen, S.The value of changes in life expectancy. Journal of Risk and Uncertainty, 1988, 1, 285–304.CrossRefGoogle Scholar
7
7.Vermeer, F., Simoons, M. L., de Swaan, C., et al. Cost-benefit analysis of early thrombolytic treatment with intracoronary streptokinase. British Heart Journal, 1988, 59, 527–34.CrossRefGoogle ScholarPubMed
8
8.Weinstein, M. C., & Stason, W. B.Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine, 1977, 296, 716–21.CrossRefGoogle ScholarPubMed